Industry View On Biosimilar Reimbursement Draws Congressional Support
This article was originally published in The Pink Sheet Daily
Executive Summary
A bipartisan group of US House members writes to the CMS chief urging him to publish a final Medicare payment rule "that provides each biosimilar with a unique code" rather than the proposed method of lumping all products referencing the same biologic into a single code.